ArticleFEMS immunology and medical microbiology2011
Selective serotonin reuptake inhibitors attenuate the antigen presentation from dendritic cells to effector T lymphocytes.
Article in FEMS immunology and medical microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04570449 (Fluoxetine to Reduce Hospitalization From COVID-19 Infection), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Psychopharmacological Therapy Positively Modulates Disease Activity in Inflammatory Bowel Disease: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Influence of antidepressant use on periodontal status: a systematic review and meta-analysis.Clinical oral investigations · 2025Pooled it
- From gut to brain: understanding the role of microbiota in inflammatory bowel disease.Frontiers in immunology · 2024Review
- Effects of Two Distinct Psychoactive Microbes,International journal of molecular sciences · 2022Article
- Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice.Frontiers in immunology · 2022Review
- Serotonin system is partially involved in immunomodulation of Nile tilapia (Frontiers in immunology · 2022Article
- Review
- Review
- Alpha-enolase involvement in intestinal and extraintestinal manifestations of celiac disease.Journal of translational autoimmunity · 2021Article
- Protective effects of desipramine on alveolar bone in experimental periodontitis.Journal of periodontology · 2020Article
- Current and Future Therapies for Psoriasis with a Focus on Serotonergic Drugs.Molecular neurobiology · 2020Review
- Prescription medication use and antinuclear antibodies in the United States, 1999-2004.Journal of autoimmunity · 2018Article
- Desipramine decreases expression of human and murine indoleamine-2,3-dioxygenases.Brain, behavior, and immunity · 2017Article
- Thirty-five Day Fluoxetine Treatment Limits Sensory-Motor Deficit and Biochemical Disorders in a Rat Model of Decompression Sickness.Frontiers in physiology · 2017Article
- Mind and body: how the health of the body impacts on neuropsychiatry.Frontiers in pharmacology · 2013Review
- Fluoxetine inhibits inflammatory response and bone loss in a rat model of ligature-induced periodontitis.Journal of periodontology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Fluoxetine, one of the selective serotonin reuptake inhibitors (SSRIs), has been found to possess immune modulation effects, in addition to its antidepressant effects. However, it remains unclear whether SSRIs can suppress the antigen-presenting function of dendritic cells (DCs). Therefore, Fluoxetine was applied to a co-culture of Aggregatibacter actinomycetemcomitans (Aa)-reactive T cells (×Aa-T) isolated from Aa-immunized mice and DCs. This resulted in the suppressed proliferation of ×Aa-T stimulated with Aa-antigen presentation by DCs. Specifically, Fluoxetine increased the extracellular 5-hydroxytryptamine (5-HT) in the ×Aa-T/DC co-culture, whereas exogenously applied 5-HT promoted T-cell proliferation in the ×Aa-T/DC co-culture, indicating that Fluoxetine-mediated suppression of ×Aa-T/DC responses cannot be attributed to extracellular 5-HT. Instead, Fluoxetine remarkably suppressed the expression of costimulatory molecule ICOS-L on DCs. Fluoxetine also promoted a greater proportion of CD86(Low) immature DCs than CD86(High) mature DCs, while maintaining the expression levels of CD80, MHC-class-II and PD-L1. These results suggested that Fluoxetine suppressed the ability of DCs to present bacterial antigens to T cells, and the resulting T-cell proliferation, in a SERT/5-HT-independent manner and that diminished expression of ICOS-L on DCs and increase of CD86(Low) immature DCs caused by Fluoxetine might be partially associated with Fluoxetine-mediated suppression of DC/T-cell responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.